AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10816058 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits
Number of subjects: 19
Study 10816058 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB circuits
Number of subjects: 19
Study 8655904 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day food record (4DFR)
Number of subjects: 290
Study 8655904 — intervention group
Group type: COMPARATOR
Intervention: Telephone recall (TR)
Number of subjects: 290
Study 8655904 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling about fat intake)
Number of subjects: 290
Study 1297896 — intervention group
Group type: EXPERIMENTAL
Intervention: New chewable, buffered ASA tablet formulation
Number of subjects: 12
Study 1297896 — intervention group
Group type: COMPARATOR
Intervention: Plain ASA tablet formulation
Number of subjects: 12
Study 6384203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 6384203 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 40
Study 30664617 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy
Number of subjects: 159
Study 30664617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-escitalopram combination
Number of subjects: 159
Study 30664617 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-mirtazapine combination
Number of subjects: 159
Study 30664617 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite-based models
Number of subjects: 159
Study 29191745 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic Light Labels
Number of subjects: 1255
Study 29191745 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Star Rating labels
Number of subjects: 1255
Study 29191745 — intervention group
Group type: COMPARATOR
Intervention: Nutrition Information Panels (control)
Number of subjects: 1255
Study 26318671 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth (text messaging-based) HIV prevention program
Number of subjects: 302
Study 24193291 — intervention group
Group type: EXPERIMENTAL
Intervention: Irsogladine maleate (IM) 4 mg/body/day for two years
Number of subjects: 305
Study 24193291 — intervention group
Group type: COMPARATOR
Intervention: Uracil-tegafur (250 mg/m2/day) for two years (Control)
Number of subjects: 305
Study 21367595 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 250 mg daily for 12 months
Number of subjects: 24
Study 18330806 — intervention group
Group type: EXPERIMENTAL
Intervention: Insole with toe separator
Number of subjects: 30
Study 18330806 — intervention group
Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 30
Study 16534529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Booters Incorporated (FBI)
Number of subjects: 176
Study 16534529 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Dietetic Treatment (IDT)
Number of subjects: 176
Study 16534529 — intervention group
Group type: COMPARATOR
Intervention: Information Booklet Only (BO)
Number of subjects: 176
Study 16534529 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 176
Study 16534529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (FBI and IDT)
Number of subjects: 176
Study 12927929 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily interferon (IFN)-beta (3 MU bid)
Number of subjects: 140
Study 12927929 — intervention group
Group type: COMPARATOR
Intervention: Once daily interferon (IFN)-beta (6 MU qd)
Number of subjects: 140
Study 12927929 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 140
Study 10773790 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose 1,6-diphosphate (FDP) administration
Number of subjects: 45
Study 10773790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9326983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac pacing at 30 beats/min above sinus rhythm
Number of subjects: 12
Study 9326983 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sodium nitroprusside
Number of subjects: 12
Study 9326983 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nifedipine
Number of subjects: 12
Study 9326983 — intervention group
Group type: COMPARATOR
Intervention: Intravenous felodipine
Number of subjects: 12
Study 9326983 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary nifedipine
Number of subjects: 12
Study 9326983 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary felodipine
Number of subjects: 12
Study 8462430 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillatory ventilation
Number of subjects: 92
Study 8462430 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 92
Study 3512747 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 5 mg/kg twice daily for eight weeks
Number of subjects: 13
Study 3512747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29582137 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymenoptera
Number of subjects: 3
Study 29582137 — intervention group
Group type: EXPERIMENTAL
Intervention: Odonata
Number of subjects: 3
Study 29582137 — intervention group
Group type: EXPERIMENTAL
Intervention: Diptera
Number of subjects: 3
Study 27829454 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week dose reduction group (N = 125)
Number of subjects: 374
Study 27829454 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-week dose reduction group (N = 120)
Number of subjects: 374
Study 27829454 — intervention group
Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (N = 129)
Number of subjects: 374
Study 24088010 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse riding therapy (six 30-minute sessions)
Number of subjects: 40
Study 22086491 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive home-based strengthening exercise program (PHSEP) for 8 weeks in addition to weekly institutional exercise therapy
Number of subjects: 36
Study 22086491 — intervention group
Group type: COMPARATOR
Intervention: Control group continued weekly institutional exercise sessions
Number of subjects: 36
Study 20737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic medical treatment
Number of subjects: 88
Study 20737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of medicine and adenoidectomy and/or tonsillectomy
Number of subjects: 88
Study 20737957 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic medical treatment and endoscopic sinus surgery
Number of subjects: 88
Study 18382340 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vision therapy/orthoptics
Number of subjects: 95
Study 18382340 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo vision therapy/orthoptics
Number of subjects: 95
Study 17119057 — intervention group
Group type: EXPERIMENTAL
Intervention: High heme diet (beef, blood sausage)
Number of subjects: 0
Study 17119057 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme supplemented diet (120 g/d red meat, baseline diet supplemented with heme iron)
Number of subjects: 0
Study 17119057 — intervention group
Group type: EXPERIMENTAL
Intervention: High heme diet (rats)
Number of subjects: 0
Study 17119057 — intervention group
Group type: COMPARATOR
Intervention: Control diet (chicken, baseline diet)
Number of subjects: 0
Study 12393528 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelation treatment
Number of subjects: 39
Study 10994157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enzyme combination product (OE; Phlogenzym(®), containing trypsin, bromelain and rutin)
Number of subjects: 2139
Study 10994157 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAID)
Number of subjects: 2139
Study 10994157 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enzyme combination product (OE)
Number of subjects: 2139
Study 8791954 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg b.d. + placebo
Number of subjects: 24
Study 8791954 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg b.d. + omeprazole 40 mg b.d.
Number of subjects: 24
Study 8791954 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.d. + placebo
Number of subjects: 24
Study 7890900 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b (3 million units, subcutaneously, 3 times a week for 3 months)
Number of subjects: 33
Study 7890900 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha‐2b
Number of subjects: 33
Study 7890900 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 33
Study 3063044 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.2 mg/kg i.v.
Number of subjects: 75
Study 3063044 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4.0 mg/kg i.v.
Number of subjects: 75
Study 3063044 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 2.0 mg/kg i.v.
Number of subjects: 75
Study 30170904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen treatment for 2 weeks
Number of subjects: 84
Study 30170904 — intervention group
Group type: COMPARATOR
Intervention: No oxygen treatment for 2 weeks
Number of subjects: 84
Study 27075216 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive treatment group (intermittent preventive application of topical corticosteroid for 1 year)
Number of subjects: 30
Study 27075216 — intervention group
Group type: COMPARATOR
Intervention: Reactive treatment group
Number of subjects: 30
Study 27075216 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive treatment group
Number of subjects: 30
Study 24152600 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive Technology and Telecare (ATT)
Number of subjects: 500
Study 24152600 — intervention group
Group type: COMPARATOR
Intervention: Equivalent community services (Control)
Number of subjects: 500
Study 21855126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma symptoms requiring albuterol (NASRAs)
Number of subjects: 285
Study 21855126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma symptoms requiring albuterol (NASRAs) during exacerbation periods
Number of subjects: 285
Study 20008205 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prophylaxis for thrombotic complications
Number of subjects: 1
Study 17898099 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins treatment with varying HDL cholesterol levels
Number of subjects: 9770
Study 17898099 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins treatment with HDL cholesterol in the highest quintile
Number of subjects: 9770
Study 15353498 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 2341
Study 15353498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2341
Study 11444637 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovision (single vision Acuvue lenses)
Number of subjects: 150
Study 11444637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Bifocal contact lenses
Number of subjects: 150
Study 11444637 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens wear
Number of subjects: 150
Study 9760347 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 9
Study 9760347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 9
Study 10155673 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy (VP: vindesine and cisplatin; CAP: cyclophosphamide, doxorubicin and cisplatin)
Number of subjects: 70
Study 10155673 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 70
Study 2234804 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone drops
Number of subjects: 0
Study 2234804 — intervention group
Group type: COMPARATOR
Intervention: Topical flurbiprofen drops
Number of subjects: 0
Study 355604 — intervention group
Group type: COMPARATOR
Intervention: Best conventional care (no chemotherapy or radiotherapy)
Number of subjects: 303
Study 355604 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU (80 mg/sq m/day on 3 successive days every 6 to 8 weeks)
Number of subjects: 303
Study 355604 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (5000 to 6000 rads to the whole brain)
Number of subjects: 303
Study 355604 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU plus radiotherapy
Number of subjects: 303
Study 31814226 — intervention group
Group type: EXPERIMENTAL
Intervention: Malic acid lozenge
Number of subjects: 110
Study 31814226 — intervention group
Group type: COMPARATOR
Intervention: Citric acid mouthwash
Number of subjects: 110
Study 30875425 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Excision and Grafting (EEG)
Number of subjects: 50
Study 30875425 — intervention group
Group type: COMPARATOR
Intervention: Delayed Excision and Grafting (DEG)
Number of subjects: 50
Study 28615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families program
Number of subjects: 0
Study 28615354 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26092291 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 676
Study 26092291 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 676
Study 23586326 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain fused to base metal alloy (BMA)
Number of subjects: 23
Study 23586326 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain fused to noble metal alloy (NMA)
Number of subjects: 23
Study 23586326 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium oxide-based ceramics
Number of subjects: 23
Study 23586326 — intervention group
Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 23
Study 21191575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g/day
Number of subjects: 45
Study 21191575 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 3 g/day
Number of subjects: 45
Study 21191575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18489015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg)
Number of subjects: 33
Study 18489015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg)
Number of subjects: 33
Study 18489015 — intervention group
Group type: COMPARATOR
Intervention: D-amphetamine (20 mg)
Number of subjects: 33
Study 18489015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16766006 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/piperaquine (DHA-PQP)
Number of subjects: 762
Study 16766006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine+artesunate (AQ+AS)
Number of subjects: 762
Study 16766006 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine+sulfadoxine/pyrimethamine (AQ+SP)
Number of subjects: 762
Study 14566693 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine (15 mg t.i.d.)
Number of subjects: 98
Study 14566693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 10784360 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II pressor dose (1-3 microg/min)
Number of subjects: 60
Study 10784360 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II subpressor dose (0.0375-0.15 microg/min)
Number of subjects: 60
Study 10784360 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II pressor dose + Losartan (50 mg)
Number of subjects: 60
Study 10784360 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II subpressor dose + Losartan (50 mg)
Number of subjects: 60
Study 10784360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (electrolyte solution)
Number of subjects: 60
Study 1833529 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 29
Study 1833529 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (12.5 mg every 5 minutes up to a maximum of 50 mg)
Number of subjects: 29
Study 1833529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 micrograms every 5 minutes up to a maximum of 100 micrograms)
Number of subjects: 29
Study 6972823 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 58
Study 6972823 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 58
Study 30347634 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Local Means (NLM) filtering
Number of subjects: 0
Study 30347634 — intervention group
Group type: COMPARATOR
Intervention: Distance-Driven MAR (DDMar)
Number of subjects: 0
Study 30347634 — intervention group
Group type: COMPARATOR
Intervention: Linear Interpolation-based MAR (LIMar)
Number of subjects: 0
Study 30347634 — intervention group
Group type: COMPARATOR
Intervention: Intensity thresholding
Number of subjects: 0
Study 28956671 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw crushed garlic (100 mg/kg body weight, 2 times a day for 4 weeks)
Number of subjects: 40
Study 26615605 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day plus standard ADHF therapy
Number of subjects: 100
Study 26615605 — intervention group
Group type: COMPARATOR
Intervention: Standard ADHF therapy alone
Number of subjects: 100
Study 24233571 — intervention group
Group type: EXPERIMENTAL
Intervention: 11% CP (low CP)
Number of subjects: 24
Study 24233571 — intervention group
Group type: EXPERIMENTAL
Intervention: 13% CP (high CP)
Number of subjects: 24
Study 22405443 — intervention group
Group type: EXPERIMENTAL
Intervention: Seclusion room
Number of subjects: 105
Study 22405443 — intervention group
Group type: COMPARATOR
Intervention: Physical restraints
Number of subjects: 105
Study 20216020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) technique for brachial plexus block
Number of subjects: 25
Study 20216020 — intervention group
Group type: COMPARATOR
Intervention: Other nerve location methods
Number of subjects: 25
Study 20216020 — intervention group
Group type: EXPERIMENTAL
Intervention: Different US-guided techniques
Number of subjects: 25
Study 17095117 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Replacement Trial (FR-trial) - water bolus (5.0 mL/kg body mass) ingested immediately pre-exercise and every 20 min during exercise (2.0 mL/kg body mass)
Number of subjects: 15
Study 17095117 — intervention group
Group type: COMPARATOR
Intervention: No Fluid Ingestion Trial (NF-trial) - no fluid ingested
Number of subjects: 15
Study 16272801 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise training (4 times a week for 6 weeks)
Number of subjects: 8
Study 16272801 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip exercise training
Number of subjects: 8
Study 16272801 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 8
Study 11864856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat evening meal (62% of energy from fat)
Number of subjects: 12
Study 11864856 — intervention group
Group type: COMPARATOR
Intervention: Low-fat evening meal (16% of energy from fat)
Number of subjects: 12
Study 10199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg/day)
Number of subjects: 66
Study 10199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg/day)
Number of subjects: 66
Study 10199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (300 mg/day)
Number of subjects: 66
Study 10199771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-cyproterone acetate (0.01 mg EE/day for the first week, 0.02 mg EE/day for the second week, 0.01 mg EE/day for the third week, followed by a pause of 7 days, then 12.5 mg CPA/day for the first 10 days of every month for 12 months)
Number of subjects: 66
Study 10199771 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EE-CPA and finasteride
Number of subjects: 66
Study 10199771 — intervention group
Group type: COMPARATOR
Intervention: Comparison of flutamide and finasteride
Number of subjects: 66
Study 10199771 — intervention group
Group type: COMPARATOR
Intervention: Comparison of flutamide and finasteride (hair diameter)
Number of subjects: 66
Study 7557767 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure technique with Penrose drains (test group)
Number of subjects: 52
Study 7557767 — intervention group
Group type: COMPARATOR
Intervention: Primary closure technique without Penrose drains (control group)
Number of subjects: 52
Study 2242455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 269
Study 2242455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy (breast conservation surgery)
Number of subjects: 269
Study 2242455 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons who offered a choice of treatment
Number of subjects: 269
Study 2242455 — intervention group
Group type: COMPARATOR
Intervention: Surgeons who favoured mastectomy
Number of subjects: 269
Study 2242455 — intervention group
Group type: COMPARATOR
Intervention: Surgeons who favoured breast conservation
Number of subjects: 269
Study 6183902 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate with leucovorin (100 mg i.v.)
Number of subjects: 36
Study 6183902 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate without leucovorin
Number of subjects: 36
Study 6183902 — intervention group
Group type: COMPARATOR
Intervention: Four different intermittent dosage schedules of methotrexate
Number of subjects: 36
Study 30889154 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg selenium yeast once daily
Number of subjects: 130
Study 30889154 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets once daily
Number of subjects: 130
Study 29535139 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) group: formula diet containing 60% of the daily energy requirement for 7 days before surgery
Number of subjects: 82
Study 29535139 — intervention group
Group type: COMPARATOR
Intervention: Control group: ad libitum food for 7 days before surgery
Number of subjects: 82
Study 26850135 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal closure protocol
Number of subjects: 233
Study 26850135 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 233
Study 24842182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound-guided adductor canal block with 0.2% ropivacaine
Number of subjects: 80
Study 24842182 — intervention group
Group type: COMPARATOR
Intervention: Sham catheter
Number of subjects: 80